PresentationShaun BagaiCEO, Secretary & Director Thank you for the opportunity, and thank you for those listening in, and I look forward to sharing our updates with you and the progress we've made to date as we are closing up an exciting year in 2025 and really planting the seeds and putting in the positive foundation for growth in 2026. My name is Shaun Bagai, CEO of RenovoRx. And here at RenovoRx, we are working on a new way to think about cancer. Unfortunately, when you think about new cancer therapeutic ...

Summary of RenovoRx Conference Call - December 09, 2025 Company Overview - **Company**: RenovoRx Inc. (NasdaqCM:RNXT) - **Industry**: Cancer therapeutics and medical devices Key Points and Arguments 1. **New Approach to Cancer Treatment**: RenovoRx is focusing on localizing therapy for cancers rather than solely targeting tumors, aiming to minimize patient toxicity while effectively treating cancer [2][3] 2. **Commercialization of RenovoCath Device**: The company has initiated the commercialization of its FDA-cleared RenovoCath device, generating over $900,000 in revenue year-to-date through Q3 2025 without a dedicated sales infrastructure [3][4] 3. **Market Potential**: The peak revenue potential for the RenovoCath device in the U.S. is estimated at over $400 million, based on indications and areas of use [4][12] 4. **TAMP Mechanism**: The proprietary Trans-Arterial Micro-Perfusion (TAMP) mechanism allows for localized chemotherapy delivery, significantly increasing drug concentration at the tumor site while reducing systemic exposure [5][8][9] 5. **Clinical Trials**: The pivotal phase III TIGeR-PaC study for locally advanced pancreatic cancer is progressing, with enrollment expected to complete in early 2026 and final data anticipated in 2027 [5][18] 6. **Patient Experience**: The TAMP procedure is outpatient, requiring only conscious sedation, and allows patients to receive treatment in about 90 minutes, contrasting with traditional chemotherapy that often requires longer hospital stays [10][11] 7. **Market Expansion**: Beyond pancreatic cancer, the device is applicable to other hypovascular tumors, including cholangiocarcinoma and non-small cell lung cancers, which could further expand the market [11][34] 8. **Sales Infrastructure**: A lean sales team has been established, with 14 centers approved to purchase the device and five actively using it, indicating strong initial market interest [14][15][26] 9. **Financial Position**: As of Q3 2025, RenovoRx reported over $10 million in cash and anticipates revenue growth in 2026, with a current cash burn of approximately $800,000 per month [24][34] 10. **Reimbursement and Margins**: The company has established reimbursement rates allowing for device pricing between $6,000 and $8,500, with current margins around 80%, expected to improve as manufacturing scales [12][35] Additional Important Content - **Regulatory Pathway**: The device was approved through the 510(k) pathway, allowing for a faster and simpler regulatory process compared to more invasive technologies [28][29] - **International Market Considerations**: While there is potential for international expansion, the focus remains on the U.S. market due to higher reimbursement rates and lower regulatory hurdles [28][29] - **Future Collaborations**: Ongoing discussions with medical device companies for potential partnerships or distribution arrangements are in place, indicating interest in the device's unique capabilities [37][38] - **Scientific Advisory Board**: The company has a strong advisory board with notable experts in oncology, enhancing its credibility and potential for clinical success [22] This summary encapsulates the key insights from the RenovoRx conference call, highlighting the company's innovative approach to cancer treatment, market potential, and strategic plans for growth.